| Literature DB >> 26196001 |
Mohammad Hossein Anbardar1, Bita Geramizadeh1, Hamid Reza Foroutan1.
Abstract
BACKGROUND: Hirschsprung's disease (HD) is a congenital intestinal motility disorder with absence of ganglion cells in the colonic wall. Diagnosis of the disease is mainly based on the identification of the lack of ganglion cells in the pathology sections of the colon which is very difficult and time consuming and also needs several serial cut sections. There are many proposed markers in this field in the literature but none of them has been satisfactory. Calretinin immunohistochemistry (IHC) has been introduced as a new diagnostic marker to overcome the problems in diagnosis of this disease about 5 years ago. However there are few studies regarding the benefits and pitfalls of this marker.Entities:
Keywords: Ganglion Cells; Hirschsprung Disease; Immunohistochemistry
Year: 2015 PMID: 26196001 PMCID: PMC4506005 DOI: 10.5812/ijp.367
Source DB: PubMed Journal: Iran J Pediatr ISSN: 2008-2142 Impact factor: 0.364
Demographic Findings of the Patients in the Study Group
| Variables | Hirschsprung Disease | Non-Hirschsprung Disease |
|---|---|---|
|
| 27 | 28 |
|
| 21.3 ± 28.1 | 27 ± 33.2 |
|
| ||
| Male | 23 (85) | 21 (75) |
| Female [ | 4 (15) | 7 (25) |
a Mean ± SD.
b No. (%).
Figure 1.Low Power View of Full Wall Thickness Section Shows Calretinin Immunoreactivity in Lamina Propria, Submucosa and Muscularis Propria (× 100)
Figure 3.Strong Cytoplasmic and Nuclear Calretinin Immunoreactivity in Ganglion Cells of Submucosa (× 250)
Figure 4.Low Power View of Full Wall Thickness Section Shows no Calretinin Immunoreactivity in Lamina Propria, Submucosa and Muscularis Propria (× 40)
Figure 6.Lamina Propria Shows no Calretinin Immunoreactivity in Nerve Fibers (× 400)
Calretinin Immunoreactivity in Aganglionic Segment of the Patients With Hirschsprung’s Disease [a]
| Case No | Type | Pathologist 1 | Pathologist 2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| ||
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Long | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Long | N | N | N | HD | N | N | N | HD |
|
| TCA | ||||||||
| (A) | N | N | N | HD | N | N | N | HD | |
| (B) | N | N | N | HD | N | N | N | HD | |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Long | N | N | N | HD | N | N | N | HD |
|
| Long | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | P | HD | N | N | P | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| TCA | ||||||||
| (A) | N | N | N | HD | N | N | N | HD | |
| (B) | N | N | N | HD | N | N | N | HD | |
|
| TCA | N | N | N | HD | P | N | N | NHD |
|
| Classic | N | N | N | HD | N | N | N | HD |
|
| TCA | P | N | N | NHD | P | N | N | NHD |
|
| TCA | ||||||||
| (A) | N | N | N | HD | N | N | N | HD | |
| (B) | N | N | N | HD | N | N | N | HD | |
|
| TCA | ||||||||
| (A) | N | N | N | HD | P | N | N | NHD | |
| (B) | N | N | N | HD | N | N | N | HD | |
a Abbreviations: Final Dx, final diagnosis; HD, Hirschsprung disease; LP, Lamina properia; MP, muscularis properia; N, negative; NHD, non-Hirschsprung disease; P, positive; SM, submucosa; TCA, total colonic aganglionosis.
b These cases had two aganglionic sections.
Calretinin Immunoreactivity in Full Wall Thickness Sections From Hirschsprung Disease (HD) and Non-Hirschsprung Disease (NHD) Patients According to Pathologist 2 [a]
| Location | Aganglionic Segment of HD | Normoganglionic Segment of HD | NHD | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 3 (9.7) | 28 (90.3) | 30 (96.7) | 1 (3.3) | 26 (83.8) | 5 (16.2) |
|
| 0 (0) | 31 (100) | 31 (100) | 0 (0) | 31 (100) | 0 (0) |
|
| 0 (0) | 31 (100) | 31 (100) | 0 (0) | 31 (100) | 0 (0) |
|
| 1 (3.3) | 30 (96.7) | 31 (100) | 0 (0) | 31 (100) | 0 (0) |
a Data are presented as No. (%).
Calretinin Immunoreactivity in Full Wall Thickness Sections From Hirschsprung Disease (HD) and Non-Hirschsprung Disease (NHD) Patients According to Pathologist 1 [a]
| Location | Aganglionic Segment of HD | Normoganglionic Segment of HD | NHD | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 1 (3.3) | 30 (96.7) | 29 (93.5) | 2 (6.5) | 27 (87.1) | 4 (12.9) |
|
| 0 (0) | 31 (100) | 31 (100) | 0 (0) | 31 (100) | 0 (0) |
|
| 0 (0) | 31 (100) | 31 (100) | 0 (0) | 31 (100) | 0 (0) |
|
| 1 (3.3) | 30 (96.7) | 31 (100) | 0 (0) | 31 (100) | 0 (0) |
a Data are presented as No. (%).
Calretinin Immunohistochemistry Results in Normoganglionic Segment of Hirschsprung Disease Patients [a]
| Case No [ | Type | Pathologist 1 | Pathologist 2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| LP | SM | MP | Final Dx | LP | SM | MP | Final Dx | ||
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Long | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | N | P | P | NG | P | P | P | NG |
|
| Classic | N | P | P | NG | N | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Long | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Long | P | P | P | NG | P | P | P | NG |
|
| Long | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| TCA | P | P | P | NG | P | P | P | NG |
|
| Classic | P | P | P | NG | P | P | P | NG |
|
| TCA | P | P | P | NG | P | P | P | NG |
a Abbreviations: Final Dx, final diagnosis; LP, lamina propria; MP, muscularis propria; N, negative; NG, normoganglionosis; SM, submucosa; P, positive; TCA, total colonic aganglionosis.
b Cases 12, 22, 26 and 27 had no normoaganglionic section.
Calretinin Immunohistochemistry Results in Non-Hirschsprung’s Disease Patients [a]
| Case No | Pathologist 1 | Pathologist 2 | ||||||
|---|---|---|---|---|---|---|---|---|
| LP | SM | MP | Final Dx | LP [ | SM | MP | Final Dx | |
|
| N | P | P | NHD | N | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | N | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| N | P | P | NHD | N | P | P | NHD |
|
| N | P | P | NHD | N | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| N | P | P | NHD | N | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
|
| P | P | P | NHD | P | P | P | NHD |
a Abbreviations: Final Dx, final diagnosis; HD, Hirschsprung disease; LP, lamina propria; MP, muscularis propria; N, negative; NHD, non-Hirschsprung disease; P, positive; SM, submucosa.
Statistical Evaluation of Calretinin Immunohistochemistry According to Both Pathologists’ Final Diagnosis, Decision on Lamina Propria and Submucosa Compare With Gold Standard [a]
| Pathologist | Kappa | P Value | Sensitivity [ | Specificity [ | PPV[ | NPV[ |
|---|---|---|---|---|---|---|
| 1 | 0.97 | < 0.001 | 96.7 | 100 | 100 | 98 |
| 2 | 0.92 | < 0.001 | 90.3 | 100 | 100 | 94.4 |
|
| ||||||
| 1 | 0.82 | < 0.001 | 96.7 | 88.2 | 83.3 | 97.8 |
| 2 | 0.77 | < 0.001 | 90.3 | 88.2 | 82.3 | 93.7 |
|
| ||||||
| 1 | 1 | < 0.001 | 100 | 100 | 100 | 100 |
| 2 | 1 | < 0.001 | 100 | 100 | 100 | 100 |
a Abbreviations: Kappa, concordance; NPV, negative predictive value; PPV, positive predictive value.
b Data are presented as %.
Distribution of Sections According to Pathologists’ Opinion [a]
| Pathologist 1 | Pathologist 2 | Number/Total, % |
|---|---|---|
|
| Aganglionosis (HD) | 28.82 (34.1) |
|
| Normoganglionosis (NonHD) | 2.82 (2.5) |
|
| Aganglionosis (HD) | 0.82 (0) |
|
| Normoganglionosis (NonHD) | 52.82 (63.4) |
a Abbreviations: HD, Hirschsprung’s disease.
Figure 2.Lamina Propria Shows Calretinin Immunoreactivity in Nerve Fibers (× 250)
Figure 7.Submucosa Shows Two Mast Cells (Arrow) Which are Stained by Calretinin and can be Used as Positive Control (× 400)